Roflumilast Plus Antipsychotics Proof of Mechanism Study in Schizophrenia

NCT02079844 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: Roflumilast
DRUG: Placebo
DRUG: Second generation antipsychotic

Sponsor

Takeda